[
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock rises Tuesday, still underperforms market",
    "summary": "Merck & Co. Inc. stock rises Tuesday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=6cccc3d26c44cedd2196730dc0f7067bcc8588ca3c70f4835340191649b277ea",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745339520,
      "headline": "Merck & Co. Inc. stock rises Tuesday, still underperforms market",
      "id": 134053740,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock rises Tuesday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=6cccc3d26c44cedd2196730dc0f7067bcc8588ca3c70f4835340191649b277ea"
    }
  },
  {
    "ts": null,
    "headline": "Cantor Fitzgerald Initiates Coverage of Merck (MRK) with Neutral Recommendation",
    "summary": "Cantor Fitzgerald Initiates Coverage of Merck (MRK) with Neutral Recommendation",
    "url": "https://finnhub.io/api/news?id=ac3d04d7708c557791142ac2e0076c7ff81e02979c0aa84fcf25619fe0b813cb",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745323488,
      "headline": "Cantor Fitzgerald Initiates Coverage of Merck (MRK) with Neutral Recommendation",
      "id": 134032750,
      "image": "",
      "related": "MRK",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=ac3d04d7708c557791142ac2e0076c7ff81e02979c0aa84fcf25619fe0b813cb"
    }
  },
  {
    "ts": null,
    "headline": "Merck Q1 Earnings Coming Up: Should You Buy the Stock Now?",
    "summary": "When Merck reports first-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.",
    "url": "https://finnhub.io/api/news?id=e0c3c0013b9e42e990986dce766827941959e3f40a005ecddc70e6daec0acff8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745321520,
      "headline": "Merck Q1 Earnings Coming Up: Should You Buy the Stock Now?",
      "id": 134038869,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "When Merck reports first-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.",
      "url": "https://finnhub.io/api/news?id=e0c3c0013b9e42e990986dce766827941959e3f40a005ecddc70e6daec0acff8"
    }
  },
  {
    "ts": null,
    "headline": "Health Canada Approves KEYTRUDA速 Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)",
    "summary": "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has approved KEYTRUDA速 (pembrolizumab), Merck's anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). The approval is based on data from the pivotal Phase 3 IND.227/KEYNOTE-483 trial, which demonstrated a statistically significant improvement",
    "url": "https://finnhub.io/api/news?id=52d99e31e129684f5687481131408ed536ca957f19d4ba4ec11fae872a048f32",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745319600,
      "headline": "Health Canada Approves KEYTRUDA速 Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)",
      "id": 134031942,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has approved KEYTRUDA速 (pembrolizumab), Merck's anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). The approval is based on data from the pivotal Phase 3 IND.227/KEYNOTE-483 trial, which demonstrated a statistically significant improvement",
      "url": "https://finnhub.io/api/news?id=52d99e31e129684f5687481131408ed536ca957f19d4ba4ec11fae872a048f32"
    }
  },
  {
    "ts": null,
    "headline": "Iovance Biotherapeutics: Only For The Brave",
    "summary": "Iovance Biotherapeutics: Only For The Brave",
    "url": "https://finnhub.io/api/news?id=30efbab55526e45b4954739567e81037252b203a424c9b7b816339547b7674a9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745305747,
      "headline": "Iovance Biotherapeutics: Only For The Brave",
      "id": 134031617,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=30efbab55526e45b4954739567e81037252b203a424c9b7b816339547b7674a9"
    }
  }
]